Cardiothoracic & vascular anesthesia
Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial
Authors' conclusion
In this single-center, randomized, placebo-controlled clinical trial of patients undergoing cardiovascular surgery, sivelestat significantly reduced ARDS incidence and 90-day all-cause mortality.
Study context
- Population
- Consecutive patients scheduled for cardiovascular surgery at a tertiary academic centre in China382 completed
- Participants
- 424 patients
- Comparison
- Sivelestat vs placebo
- Sivelestatn = 190
- Placebon = 192reference
- Primary endpoint
- Incidence of acute respiratory distress syndrome (ARDS)
Methodological detailssingle-centre, placebo-controlled
- Single-centre
- Placebo-controlled
Primary result
As reported in the abstract
ARDS
P < 0.001
Secondary outcomes
90-day mortality
P = 0.02
Postoperative inflammatory biomarkers (neutrophil elastase, interleukin 6)
- Significantly reduced in the sivelestat group
Safety
Adverse events
- Did not differ between groups
Original publication
Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial. JAMA Netw Open. Published 2 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →